Cargando…

Surveillance of women at high risk for hereditary ovarian cancer is inefficient

To determine the effectiveness of annual gynaecological screening (pelvic examination, transvaginal ultrasound, and CA-125), a prospective cohort study of women at high risk for hereditary ovarian cancer was conducted. Women were offered DNA analysis followed by either annual screening or prophylact...

Descripción completa

Detalles Bibliográficos
Autores principales: Oei, A L, Massuger, L F, Bulten, J, Ligtenberg, M J, Hoogerbrugge, N, de Hullu, J A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361371/
https://www.ncbi.nlm.nih.gov/pubmed/16495917
http://dx.doi.org/10.1038/sj.bjc.6603015
_version_ 1782153200133996544
author Oei, A L
Massuger, L F
Bulten, J
Ligtenberg, M J
Hoogerbrugge, N
de Hullu, J A
author_facet Oei, A L
Massuger, L F
Bulten, J
Ligtenberg, M J
Hoogerbrugge, N
de Hullu, J A
author_sort Oei, A L
collection PubMed
description To determine the effectiveness of annual gynaecological screening (pelvic examination, transvaginal ultrasound, and CA-125), a prospective cohort study of women at high risk for hereditary ovarian cancer was conducted. Women were offered DNA analysis followed by either annual screening or prophylactic bilateral salpingo-oophorectomy (BSO). Study population consisted of 512 high-risk women (median follow-up 2.07 years, range 0–9.4 years): 265 women (52%) had a BRCA mutation. Persisting abnormalities indicated diagnostic surgery in 24 women resulting in one primary ovarian cancer FIGO stage IIIc was found. The effectiveness of screening was studied by calculating the probability of finding ovarian cancers in the BRCA-1 and BRCA-2 carrier group and comparing this to the identified number of ovarian cancers. The number of ovarian cancer patients found at surveillance was in accordance with the predicted number of ovarian cancers. A total number of 169 women underwent prophylactic BSO: one ovarian cancer stage IIb was found. In conclusion, the surveillance programme for hereditary ovarian cancer does identify patients with ovarian cancer but is very inefficient considering the high number of surveillance visits and the advanced stage of ovarian cancer in the identified patient. For prevention of advanced stage ovarian cancer, prophylactic BSO from age 35–40 years is a more efficient alternative.
format Text
id pubmed-2361371
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23613712009-09-10 Surveillance of women at high risk for hereditary ovarian cancer is inefficient Oei, A L Massuger, L F Bulten, J Ligtenberg, M J Hoogerbrugge, N de Hullu, J A Br J Cancer Clinical Study To determine the effectiveness of annual gynaecological screening (pelvic examination, transvaginal ultrasound, and CA-125), a prospective cohort study of women at high risk for hereditary ovarian cancer was conducted. Women were offered DNA analysis followed by either annual screening or prophylactic bilateral salpingo-oophorectomy (BSO). Study population consisted of 512 high-risk women (median follow-up 2.07 years, range 0–9.4 years): 265 women (52%) had a BRCA mutation. Persisting abnormalities indicated diagnostic surgery in 24 women resulting in one primary ovarian cancer FIGO stage IIIc was found. The effectiveness of screening was studied by calculating the probability of finding ovarian cancers in the BRCA-1 and BRCA-2 carrier group and comparing this to the identified number of ovarian cancers. The number of ovarian cancer patients found at surveillance was in accordance with the predicted number of ovarian cancers. A total number of 169 women underwent prophylactic BSO: one ovarian cancer stage IIb was found. In conclusion, the surveillance programme for hereditary ovarian cancer does identify patients with ovarian cancer but is very inefficient considering the high number of surveillance visits and the advanced stage of ovarian cancer in the identified patient. For prevention of advanced stage ovarian cancer, prophylactic BSO from age 35–40 years is a more efficient alternative. Nature Publishing Group 2006-03-27 2006-02-21 /pmc/articles/PMC2361371/ /pubmed/16495917 http://dx.doi.org/10.1038/sj.bjc.6603015 Text en Copyright © 2006 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Clinical Study
Oei, A L
Massuger, L F
Bulten, J
Ligtenberg, M J
Hoogerbrugge, N
de Hullu, J A
Surveillance of women at high risk for hereditary ovarian cancer is inefficient
title Surveillance of women at high risk for hereditary ovarian cancer is inefficient
title_full Surveillance of women at high risk for hereditary ovarian cancer is inefficient
title_fullStr Surveillance of women at high risk for hereditary ovarian cancer is inefficient
title_full_unstemmed Surveillance of women at high risk for hereditary ovarian cancer is inefficient
title_short Surveillance of women at high risk for hereditary ovarian cancer is inefficient
title_sort surveillance of women at high risk for hereditary ovarian cancer is inefficient
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361371/
https://www.ncbi.nlm.nih.gov/pubmed/16495917
http://dx.doi.org/10.1038/sj.bjc.6603015
work_keys_str_mv AT oeial surveillanceofwomenathighriskforhereditaryovariancancerisinefficient
AT massugerlf surveillanceofwomenathighriskforhereditaryovariancancerisinefficient
AT bultenj surveillanceofwomenathighriskforhereditaryovariancancerisinefficient
AT ligtenbergmj surveillanceofwomenathighriskforhereditaryovariancancerisinefficient
AT hoogerbruggen surveillanceofwomenathighriskforhereditaryovariancancerisinefficient
AT dehulluja surveillanceofwomenathighriskforhereditaryovariancancerisinefficient